Search

Your search keyword '"Tsuneyoshi, Kengo"' showing total 16 results
Start Over Author "Tsuneyoshi, Kengo" Publication Year Range Last 10 years
16 results on '"Tsuneyoshi, Kengo"'

1. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

Author

Shibuki, Taro, Otsuka, Taiga, Shimokawa, Mototsugu, Nakazawa, Junichi, Arima, Shiho, Fukahori, Masaru, Miwa, Keisuke, Okabe, Yoshinobu, Koga, Futa, Ueda, Yujiro, Kubotsu, Yoshihito, Makiyama, Akitaka, Shimokawa, Hozumi, Takeshita, Shigeyuki, Nishikawa, Kazuo, Komori, Azusa, Otsu, Satoshi, Hosokawa, Ayumu, Sakai, Tatsunori, Oda, Hisanobu, Kawahira, Machiko, Arita, Shuji, Honda, Takuya, Taguchi, Hiroki, Tsuneyoshi, Kengo, Kawaguchi, Yasunori, Fujita, Toshihiro, Sakae, Takahiro, Nio, Kenta, Ide, Yasushi, Ureshino, Norio, Shirakawa, Tsuyoshi, Mizuta, Toshihiko, and Mitsugi, Kenji

Published
2024
Full Text
View/download PDF

2. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer

Author

Kodama, Tomoko, Imajima, Takashi, Shimokawa, Mototsugu, Otsuka, Taiga, Kawahira, Masahiro, Nakazawa, Junichi, Hori, Takeshi, Shibuki, Taro, Arima, Shiho, Ido, Akio, Miwa, Keisuke, Okabe, Yoshinobu, Koga, Futa, Ueda, Yujiro, Kubotsu, Yoshihito, Shimokawa, Hozumi, Takeshita, Shigeyuki, Nishikawa, Kazuo, Komori, Azusa, Otsu, Satoshi, Hosokawa, Ayumu, Sakai, Tatsunori, Sakai, Kenji, Oda, Hisanobu, Kawahira, Machiko, Arita, Shuji, Honda, Takuya, Taguchi, Hiroki, Tsuneyoshi, Kengo, Kawaguchi, Yasunori, Fujita, Toshihiro, Sakae, Takahiro, Shirakawa, Tsuyoshi, Mizuta, Toshihiko, and Mitsugi, Kenji

Published
2024
Full Text
View/download PDF

3. Feasibility and safety of EUS-guided biliary drainage in inexperienced centers: a multicenter study in southwest Japan

Author

Koga, Takehiko, Ishida, Yusuke, Hashigo, Shunpei, Shimokawa, Yuzo, Harima, Hirofumi, Okamoto, Kazuhisa, Ohno, Akihisa, Miyagahara, Tsukasa, Fujita, Toshihiro, Fukuchi, Satoshi, Takahashi, Kosuke, Taguchi, Hiroki, Araki, Norimasa, Ohtsuka, Yuichiro, Uekitani, Toshiyuki, Tsuneyoshi, Kengo, Akiyama, Takumi, Ishigaki, Noriko, Maruo, Toru, Saito, Hirokazu, Ihara, Ryo, Yamasuji, Akihiro, Oe, Shinji, Yoshinari, Motohiro, Sagami, Ryota, Fujimori, Nao, Fukuda, Yoshio, Ozawa, Eisuke, Jikuya, Kenichi, Shinohara, Hiroki, Sen-yo, Manabu, Ueki, Toshiharu, Tsuchiya, Naoaki, Kitaguchi, Takanori, Matsumoto, Keisuke, Fukuyama, Makoto, and Hirai, Fumihito

Published
2024
Full Text
View/download PDF

4. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservational study (NAPOLEON-2)

Author

Kodama, Tomoko, primary, Imajima, Takashi, additional, Shimokawa, Mototsugu, additional, Otsuka, Taiga, additional, Kawahira, Masahiro, additional, Nakazawa, Junichi, additional, Hori, Takeshi, additional, Shibuki, Taro, additional, Arima, Shiho, additional, Ido, Akio, additional, Miwa, Keisuke, additional, Okabe, Yoshinobu, additional, Koga, Futa, additional, Ueda, Yujiro, additional, Kubotsu, Yoshihito, additional, Shimokawa, Hozumi, additional, Takeshita, Shigeyuki, additional, Nishikawa, Kazuo, additional, Komori, Azusa, additional, Otsu, Satoshi, additional, Hosokawa, Ayumu, additional, Sakai, Tatsunori, additional, Sakai, Kenji, additional, Oda, Hisanobu, additional, Kawahira, Machiko, additional, Arita, Shuji, additional, Honda, Takuya, additional, Taguchi, Hiroki, additional, Tsuneyoshi, Kengo, additional, Kawaguchi, Yasunori, additional, Fujita, Toshihiro, additional, Sakae, Takahiro, additional, Shirakawa, Tsuyoshi, additional, Mizuta, Toshihiko, additional, and Mitsugi, Kenji, additional

Published
2024
Full Text
View/download PDF

7. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observational study (NAPOLEON-2)

Author

Kodama, Tomoko, primary, Imajima, Takashi, additional, Shimokawa, Mototsugu, additional, Otsuka, Taiga, additional, Kawahira, Masahiro, additional, Nakazawa, Junichi, additional, Hori, Takeshi, additional, Shibuki, Taro, additional, Arima, Shiho, additional, Ido, Akio, additional, Miwa, Keisuke, additional, Okabe, Yoshinobu, additional, Koga, Futa, additional, Ueda, Yujiro, additional, Kubotsu, Yoshihito, additional, Shimokawa, Hozumi, additional, Takeshita, Shigeyuki, additional, Nishikawa, Kazuo, additional, Komori, Azusa, additional, Otsu, Satoshi, additional, Hosokawa, Ayumu, additional, Sakai, Tatsunori, additional, Sakai, Kenji, additional, Oda, Hisanobu, additional, Kawahira, Machiko, additional, Arita, Shuji, additional, Honda, Takuya, additional, Taguchi, Hiroki, additional, Tsuneyoshi, Kengo, additional, Kawaguchi, Yasunori, additional, Fujita, Toshihiro, additional, Sakae, Takahiro, additional, Shirakawa, Tsuyoshi, additional, Mizuta, Toshihiko, additional, and Mitsugi, Kenji, additional

Published
2023
Full Text
View/download PDF

8. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

Author

Shibuki, Taro, primary, Otsuka, Taiga, additional, Shimokawa, Mototsugu, additional, Nakazawa, Junichi, additional, Arima, Shiho, additional, Fukahori, Masaru, additional, Miwa, Keisuke, additional, Okabe, Yoshinobu, additional, Koga, Futa, additional, Ueda, Yujiro, additional, Kubotsu, Yoshihito, additional, Makiyama, Akitaka, additional, Shimokawa, Hozumi, additional, Takeshita, Shigeyuki, additional, Nishikawa, Kazuo, additional, Komori, Azusa, additional, Otsu, Satoshi, additional, Hosokawa, Ayumu, additional, Sakai, Tatsunori, additional, Oda, Hisanobu, additional, Kawahira, Machiko, additional, Arita, Shuji, additional, Honda, Takuya, additional, Taguchi, Hiroki, additional, Tsuneyoshi, Kengo, additional, Kawaguchi, Yasunori, additional, Fujita, Toshihiro, additional, Sakae, Takahiro, additional, Nio, Kenta, additional, Ide, Yasushi, additional, Ureshino, Norio, additional, Shirakawa, Tsuyoshi, additional, Mizuta, Toshihiko, additional, and Mitsugi, Kenji, additional

Published
2023
Full Text
View/download PDF

10. Comparison of recurrent biliary obstruction with the use of metal and plastic stents in EUS-guided biliary drainage: A propensity score-matched analysis

Author

Hashimoto, Shinichi, primary, Iwashita, Yuji, additional, Taguchi, Hiroki, additional, Tanoue, Shiroh, additional, Ohi, Takayuki, additional, Shibata, Ryusuke, additional, Haraguchi, Tomoaki, additional, Kamikihara, Yusuke, additional, Toyodome, Koshiro, additional, Kojima, Issei, additional, Araki, Norimasa, additional, Tsuneyoshi, Kengo, additional, Nakamura, Yoshitaka, additional, Fujita, Toshihiro, additional, Hinokuchi, Makoto, additional, Iwaya, Hiromichi, additional, Arima, Shiho, additional, Sasaki, Fumisato, additional, Kanmura, Shuji, additional, and Ido, Akio, additional

Published
2023
Full Text
View/download PDF

11. RECURRENT BILIARY OBSTRUCTION IN COMPARISON BETWEEN METALLIC AND PLASTIC STENT FOR ENDOSCOPIC ULTRASONOGRAPHY-GUIDED BILIARY DRAINAGE BY USING PROPENSITY SCORE MATCHING ANALYSIS

Author

Taguchi, Hiroki, primary, Hashimoto, Shinichi, additional, Iwashita, Yuji, additional, Tanoue, Shiroh, additional, Shiibata, Ryusuke, additional, Kojima, Issei, additional, Tsuneyoshi, Kengo, additional, Nakamura, Yoshitaka, additional, Fujita, Toshihiro, additional, Hinokuchi, Makoto, additional, Iwaya, Hiromichi, additional, and Ido, Akio, additional

Published
2022
Full Text
View/download PDF

12. 上下部消化管内視鏡検査における下部消化管内視鏡の挿入性の検討

Author

MATSUOKA, Satoru, MAEDA, Hidehito, SASAKI, Fumisato, TSUNEYOSHI, Kengo, KABAYAMA, Masayuki, KANMURA, Shuji, and IDO, Akio

Subjects
bidirectional endoscopy, difficult colonoscopy case, colonoscopy insertion
Abstract

OBJECTIVES: Same-day bidirectional endoscopy (BDE) has become a commonly used. Several studies have identified that the optimal sequence of a same-day BDE was esophagogastroduodenoscopy (EGD) followed by colonoscopy (CS). However, in recent years there are no reports from Japanese facilities regarding the difficulty of colonoscopy insertion along with a same-day BDE. In this study, we sought to clarify CS difficulties if EGD was performed first followed by CS on the same-day.METHODS: This study was a single-center retrospective study, and included 61 patients who underwent EGD followed by CS (E-C group) and 120 patients who underwent CS only (CS only group). We defined a “difficult CS case” as one that required ≥650 s for colonoscope insertion.RESULTS: The numbers of difficult CS cases were not significantly different between the E-C and CS only groups (p = 0.131). Furthermore, no correlations existed between EGD examination times and colonoscope insertion times (Spearman = 0.096). In addition, for patients whose body mass index (BMI) was

Published
2022

14. Factors Associated with the Technical Success of Bilateral Endoscopic Metallic Stenting with Partial Stent-In-Stent Placement in Patients with Malignant Hilar Biliary Obstruction

Author

Fujita, Toshihiro, primary, Hashimoto, Shinichi, additional, Tanoue, Shiroh, additional, Tsuneyoshi, Kengo, additional, Nakamura, Yoshitaka, additional, Hinokuchi, Makoto, additional, Iwaya, Hiromichi, additional, Arima, Shiho, additional, Iwashita, Yuji, additional, Sasaki, Fumisato, additional, Taguchi, Hiroki, additional, Kanmura, Shuji, additional, and Ido, Akio, additional

Published
2019
Full Text
View/download PDF

16. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies.

Author

Araki T, Kawahira M, Shimokawa M, Otsuka T, Hayashi K, Sonoda Y, Honda T, Nakao K, Shibuki T, Nakazawa J, Arima S, Fukahori M, Miwa K, Koga F, Ueda Y, Kubotsu Y, Makiyama A, Shimokawa H, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Oda H, Arita S, Taguchi H, Tsuneyoshi K, Kawaguchi Y, Fujita T, Sakae T, Nio K, Ide Y, Ureshino N, Shirakawa T, Mizuta T, and Mitsugi K

Abstract

Introduction: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer, compared with gemcitabine (GEM). However, whether PFS is a surrogate marker of OS in pancreatic cancer chemotherapy focusing on FOLFIRINOX or GEM plus nab-paclitaxel remains unknown. We aimed to verify whether PFS can be a surrogate marker of OS in prognosis prediction., Methods: This was an integrated analysis of the NAPOLEON study and retrospective cohort of the NAPOLEON-2 study - a multicenter observational study conducted in Japan, using real-world data. The primary and secondary endpoints were OS and PFS, respectively. The correlation between OS and PFS in first- and second-line treatments was assessed using Method of Moments estimation. An analysis was performed in patients with confirmed OS at the end of follow-up. The NAPOLEON-2 cohort included only patients who received 5-fluorouracil, leucovorin, and nanoliposomal irinotecan (NFF) as second-line treatment., Results: Among 479 patients, the correlation between PFS and OS from first- and second-line chemotherapies was calculated in 310 and 225 patients, respectively. The R-squared values for the correlation between PFS and OS from first- and second-line chemotherapies were 0.74 and 0.76, respectively. There was no statistically significant difference in first-line treatment between the FOLFIRINOX and GEM plus nab-paclitaxel groups (p = 0.92). Therefore, the FOLFIRINOX group may not have shown a stronger correlation than the NFF group., Conclusion: PFS can be a surrogate marker of OS in first- and second-line therapies. Appropriate prognostic estimation might contribute to proper treatment selection., (© 2024 S. Karger AG, Basel.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results